Nitrogen-containing heterocyclic compounds as well as pharmaceutical composition and application thereof
A compound and heterocyclic technology, applied in the field of nitrogen-containing heterocyclic compounds and their pharmaceutical compositions, can solve problems such as weak activity
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0082] 8-(6-Methoxypyridin-3-yl)-1-(4-(piperazin-1-yl)-3-trifluoromethylphenyl)-imidazo[1,5-a]quinoxaline -4(5H)-ketone (RI-101)
[0083] 8-(6-methoxypyridin-3-yl)-1-(4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl)imidazo[1,5-a]quinoxalin-4(5H)-one(RI -101)
[0084]
[0085] Synthesis of compound 1-2a: In a 500 ml reaction flask, compound 1-1a (24 g, 100 mmol), N-Boc-piperazine (22.35 g, 120 mmol) and K 2 CO 3 (20.73 g, 150 mmol) was added to DMSO (100 ml), and the reaction was heated at 120° C. for 24 h. The reaction was completed, quenched by adding water, extracted with ethyl acetate (200ml×3), washed with water and saturated sodium chloride solution, the organic layers were combined, dried over anhydrous sodium sulfate, and rotary-evaporated under reduced pressure to obtain the crude product, which was purified by column chromatography ( ethyl acetate:petroleum ether=1:10) to obtain compound 1-2a as a white solid 13g with a yield of 31%. 1 H NMR (400MHz, CDCl 3 )δ7....
Embodiment 2
[0094] 8-(6-Ethoxypyridin-3-yl)-1-(4-(piperazin-1-yl)-3-trifluoromethylphenyl)-imidazo[1,5-a]quinoxaline -4(5H)-ketone (RI-102)
[0095] 8-(6-ethoxypyridin-3-yl)-1-(4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl)imidazo[1,5-a]quino xalin-4(5H)-one( RI-102)
[0096]
[0097] The synthesis method was the same as that of Example 1, the white solid was 0.2 g, and the yield was 72%.
[0098] 1 H NMR (400MHz, CD 3 OD)δ8.08(s,2H),8.00(d,J=7.6Hz,1H),7.85(s,1H),7.81(d,J=8.0Hz,1H),7.57-7.59(m,2H) ,7.40(d,J=8.4Hz,1H),7.21(s,1H),6.71(d,J=8.4Hz,1H),4.32(q,J=6.8Hz,2H),3.16-3.21(m, 8H), 1.39 (t, J=6.8Hz, 3H); ESI-MS: m / z 535.1[M+H] + .
Embodiment 3
[0100] 1-(4-(Piperazin-1-yl)-3-trifluoromethylphenyl)-8-(pyridin-3-yl)-imidazo[1,5-a]quinoxaline-4(5H) - Ketone (RI-103)
[0101] 1-(4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl)-8-(pyridin-3-yl)imidazo[1,5-a]quinoxalin-4(5H)-one(RI-103 )
[0102]
[0103] The synthesis method was the same as that of Example 1, the white solid was 0.13 g, and the yield was 78%.
[0104] 1 H NMR (400MHz, CD 3 OD)δ8.47-8.49(m,1H),8.44(d,J=1.6Hz,1H),8.05-8.08(m,2H),7.98(d,J=8.4Hz,1H),7.75(d, J=8.4Hz, 1H), 7.66-7.70(m, 2H), 7.45(d, J=8.4Hz, 1H), 7.38-7.41(m, 1H), 7.36(s, 1H), 2.98-3.11(m ,8H); ESI-MS: m / z 491.1 [M+H] + .
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


